A positive phase three trial result in a hard-to-treat cancer adds fresh momentum to one of AstraZeneca's most important growth drivers.
Liver cancer is one of the most difficult cancers to treat, and for patients whose tumours cannot be surgically removed, options have historically been limited.
That is what makes AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) latest clinical trial result significant.
The FTSE 100 drugmaker has shown that its immunotherapy Imfinzi, used in combination with three other treatments, can meaningfully delay disease progression in patients with unresectable hepatocellular carcinoma, the most common form of liver cancer, compared with the standard treatment alone.
Immunotherapies work by helping the body's own immune system recognise and attack cancer cells, rather than using chemotherapy to kill them directly.
The result, from a large-scale phase three trial called EMERALD-3, is the kind of rigorous clinical evidence that regulators require before approving a new treatment, meaning a formal application to bring the combination to market is now a realistic near-term prospect.
For AstraZeneca, the commercial implications are considerable.
Citi, which rates the company a buy, already forecasts Imfinzi will generate peak annual sales of $11 billion by 2030, a figure roughly 20% above what most City analysts currently expect, and this trial result helps support that case.
That puts the product in the super-blockbuster category, which is any drug with annual revenues above $10 billion.
Imfinzi is already approved in lung, bladder and bile duct cancers, and further trial readouts in bladder and oesophageal cancers are expected later this year.
Each successful indication adds another layer of revenue to what is rapidly becoming one of the most versatile drugs in AstraZeneca's portfolio, and a central pillar of its growth story.